Patents by Inventor Daniel J. Schneider
Daniel J. Schneider has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150148237Abstract: The present disclosure describes the identification and use of aptamers and photoaptamers having slower dissociation rate constants than those obtained using previously described methods. Specifically, the present disclosure describes methods for the identification and use of aptamers to one or more targets within a histological or cytological sample, which have slow rates of dissociation. The aptamers may be used to assess localization, relative density, and presence or absence of one or more targets in cytological and histological samples. Targets may be selected that are specific and diagnostic of a given disease state for which the sample was collected. The aptamers may also be used to introduce target specific signal moieties. In addition to target identification, the aptamers may be used to amplify signal generation through a variety of methods.Type: ApplicationFiled: January 27, 2015Publication date: May 28, 2015Inventors: Dominic Zichi, Sheri K. Wilcox, Chris Bock, Daniel J. Schneider, Bruce Eaton, Larry Gold, Thale C. Jarvis, Jeffrey D. Carter
-
Patent number: 8975026Abstract: The present disclosure describes the identification and use of aptamers and photoaptamers having slower dissociation rate constants than those obtained using previously described methods. Specifically, the present disclosure describes methods for the identification and use of aptamers to one or more targets within a histological or cytological sample, which have slow rates of dissociation. The aptamers may be used to assess localization, relative density, and presence or absence of one or more targets in cytological and histological samples. Targets may be selected that are specific and diagnostic of a given disease state for which the sample was collected. The aptamers may also be used to introduce target specific signal moieties. In addition to target identification, the aptamers may be used to amplify signal generation through a variety of methods.Type: GrantFiled: July 9, 2010Date of Patent: March 10, 2015Assignee: SomaLogic, Inc.Inventors: Dominic Zichi, Sheri K. Wilcox, Chris Bock, Daniel J. Schneider, Bruce Eaton, Larry Gold, Thale C. Jarvis, Jeffrey D. Carter
-
Patent number: 8975388Abstract: The present disclosure describes improved SELEX methods for producing aptamers that are capable of binding to target molecules and improved photoSELEX methods for producing photoreactive aptamers that are capable of both binding and covalently crosslinking to target molecules. Specifically, the present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. In addition, the disclosure describes aptamer constructs that include a variety of functionalities, including a cleavable element, a detection element, and a capture or immobilization element.Type: GrantFiled: May 23, 2011Date of Patent: March 10, 2015Assignee: Somalogic, Inc.Inventors: Dominic Zichi, Sheri K. Wilcox, Chris Bock, Daniel J. Schneider, Bruce Eaton, Larry Gold
-
Patent number: 8945830Abstract: The present disclosure describes methods, devices, reagents, and kits for the detection of one or more target molecules that may be present in a test sample. In one embodiment, a test sample is contacted with an aptamer that includes a tag and has a specific affinity for a target molecule. An aptamer affinity complex that includes an aptamer bound to its target molecule is allowed to form. If the test sample contains the target molecule, an aptamer affinity complex will generally form in the test sample. The aptamer affinity complex is optionally converted to an aptamer covalent complex that includes an aptamer covalently bound to its target molecule. The aptamer affinity complex (or optional aptamer covalent complex) can then be detected and/or quantified using any of a variety of methods known to one skilled in the art, including using a solid support, using mass spectrometry, and using quantitative polymerase chain reaction (Q-PCR).Type: GrantFiled: August 20, 2010Date of Patent: February 3, 2015Assignee: SomaLogic, Inc.Inventors: James R. Heil, Daniel J. Schneider, Daniel T. Nieuwlandt, Sheri K. Wilcox, Dominic Zichi, Todd Gander, Bruce Eaton, Larry Gold
-
Publication number: 20140315986Abstract: Aptamers that bind IL-6 are provided. Pharmaceutical compositions comprising IL-6 aptamers are provided, as well as methods of treating conditions using the aptamers are also provided.Type: ApplicationFiled: March 12, 2014Publication date: October 23, 2014Applicants: Otsuka Pharmaceutical Co., Ltd., SomaLogic, Inc.Inventors: Shashi Gupta, Masao Hirota, Daniel J. Schneider, Tomoki Suzuki, Thale C. Jarvis, Yuichi Ishikawa, Ikuo Murakami, Amy Gelinas, Sheela Waugh, Nebojsa Janjic
-
Publication number: 20140249043Abstract: The present disclosure describes methods, devices, reagents, and kits for the detection of one or more target molecules that may be present in a test sample. The described methods, devices, kits, and reagents facilitate the detection and quantification of a non-nucleic acid target (e.g., a protein target) in a test sample by detecting and quantifying a nucleic acid (i.e., an aptamer). The methods described create a nucleic acid surrogate for a non-nucleic acid target, thus allowing the wide variety of nucleic acid technologies, including amplification, to be applied to a broader range of desired targets, especially protein targets. The disclosure further describes aptamer constructs that facilitate the use of aptamers in a variety of analytical detection applications.Type: ApplicationFiled: February 10, 2014Publication date: September 4, 2014Applicant: SOMALOGIC, INC.Inventors: Daniel J. Schneider, Dan Nieuwlandt, Bruce Eaton, Martin Stanton, Shashi Gupta, Stephan Kraemer, Dominic Zichi, Larry Gold
-
Publication number: 20140081011Abstract: The present disclosure relates generally to the field of nucleic acids and, more particularly, to aptamers capable of binding to 4-1BB; pharmaceutical compositions comprising such 4-1BB aptamers; and methods of making and using the same.Type: ApplicationFiled: November 19, 2013Publication date: March 20, 2014Applicant: SOMALOGIC, INC.Inventors: Jonathan Vaught, Daniel I. Resnicow, Sheela Waugh, Sheri K. Wilcox, Daniel J. Schneider
-
Patent number: 8598140Abstract: The present disclosure relates generally to the field of nucleic acids and, more particularly, to aptamers capable of binding to ?-NGF; pharmaceutical compositions comprising such ?-NGF aptamers; and methods of making and using the same.Type: GrantFiled: April 12, 2011Date of Patent: December 3, 2013Assignees: SomaLogic, Inc., OTSUKA Pharmaceutical Co., Ltd.Inventors: Daniel J. Schneider, Akihiko Hisaminato, Sheela Waugh, Daniel Resnicow, Akira Nagabukuro, Toshihide Ono
-
Patent number: 8409795Abstract: The present disclosure describes improved SELEX methods for generating nucleic acid ligands that are capable of binding to target molecules and improved photoSELEX methods for generating photoreactive nucleic acid ligands that are capable of both binding and covalently crosslinking to target molecules. The disclosure further describes nucleic acid libraries having expanded physical and chemical properties and their use in SELEX and photoSELEX; methods for increasing the crosslinking efficiencies of photoaptamers; methods for producing photoaptamers having selective modifications that enhance functionality and minimize non-specific photoreactions; and methods for generating truncated nucleic acid ligands from nucleic acid ligands of longer length. The disclosure further describes aptamers and photoaptamers obtained by using any of the foregoing.Type: GrantFiled: July 17, 2008Date of Patent: April 2, 2013Assignee: Somalogic, Inc.Inventors: Daniel J. Schneider, Sheri K. Wilcox, Dominic Zichi, Dan Nieuwlandt, Jeff Carter, Larry Gold
-
Patent number: 8404830Abstract: The present disclosure is directed to the field of nucleic acid chemistry, specifically to 5-position modified uridines, as well as, oligonucleotides comprising said 5-position modified uridines. The present disclosure describes methods for producing aptamers comprising said 5-position modified uridines that are capable of binding to target molecules.Type: GrantFiled: December 15, 2010Date of Patent: March 26, 2013Assignee: SomaLogic, Inc.Inventors: Dominic Zichi, Sheri K. Wilcox, Chris Bock, Daniel J. Schneider, Bruce Eaton, Larry Gold
-
Publication number: 20130012693Abstract: The present disclosure relates generally to the field of nucleic acids and, more particularly, to aptamers capable of binding to ?-NGF; pharmaceutical compositions comprising such ?-NGF aptamers; and methods of making and using the same.Type: ApplicationFiled: April 12, 2011Publication date: January 10, 2013Applicants: OTSUKA PHARMACEUTICAL CO., LTD., SOMALOGIC, INC.Inventors: Daniel J. Schneider, Akihiko Hisaminato, Sheela Waugh, Daniel Resnicow, Akira Nagabukuro, Toshihide Ono
-
Publication number: 20120322862Abstract: The present disclosure relates generally to the field of nucleic acids and, more particularly, to aptamers capable of binding to 4-1BB; pharmaceutical compositions comprising such 4-1BB aptamers; and methods of making and using the same.Type: ApplicationFiled: March 3, 2011Publication date: December 20, 2012Applicant: SOMALOGIC, INC.Inventors: Jonathan Vaught, Daniel I. Resnicow, Sheela Waugh, Sheri K. Wilcox, Daniel J. Schneider
-
Publication number: 20120141467Abstract: Provided herein is a method for treating a tracheo-bronchial-alveolar tract disease in a subject in need thereof, the method comprising the step of administering to a subject in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of ascorbate or a derivative thereof. Also provided is a method for treating non-Hodgkin's lymphoma in a subject in need thereof, the method comprising the step of administering to the subject in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of ascorbate or a derivative thereof.Type: ApplicationFiled: December 3, 2010Publication date: June 7, 2012Inventor: Daniel J. Schneider
-
Publication number: 20120115752Abstract: The present disclosure describes the identification and use of aptamers and photoaptamers having slower dissociation rate constants than those obtained using previously described methods. Specifically, the present disclosure describes methods for the identification and use of aptamers to one or more targets within a histological or cytological sample, which have slow rates of dissociation. The aptamers may be used to assess localization, relative density, and presence or absence of one or more targets in cytological and histological samples. Targets may be selected that are specific and diagnostic of a given disease state for which the sample was collected. The aptamers may also be used to introduce target specific signal moieties. In addition to target identification, the aptamers may be used to amplify signal generation through a variety of methods.Type: ApplicationFiled: July 9, 2010Publication date: May 10, 2012Applicant: SOMALOGIC, INC.Inventors: Dominic Zichi, Sheri K. Wilcox, Chris Bock, Daniel J. Schneider, Bruce Eaton, Larry Gold, Thale C. Jarvis, Jeffrey D. Carter
-
Patent number: 8071288Abstract: The present invention provides novel methods and reagents for detecting the binding of protein targets to nucleic acid ligands. Using Universal Protein Stains (UPS), proteins bound by nucleic acid ligands may be labeled with a detectable moiety. The methods and reagents are particularly useful for the detection of protein targets bound to multiplexed arrays of nucleic acid ligands. The present invention also provides novel methods for the multiplexed evaluation of photocrosslinking nucleic acid ligands. The methods allow one simultaneously to: (1) evaluate the performance (dynamic range) of a plurality of photocrosslinking nucleic acid ligands; and (2) assess the specificity of each photocrosslinking nucleic acid ligand for its cognate target protein. Photocrosslinking nucleic acid ligands with the most desirable properties can then be selected for use in diagnostic and prognostic medical assays.Type: GrantFiled: February 12, 2008Date of Patent: December 6, 2011Assignee: SomaLogic, Inc.Inventors: Larry Gold, Jonathan Drew Smith, Dominic Zichi, Daniel J. Schneider, Chad Greef
-
Publication number: 20110274703Abstract: The invention relates to methods for the diagnosis, prognosis, and treatment of non-dermal fibrosis, including lung (or pulmonary) fibrosis.Type: ApplicationFiled: May 4, 2011Publication date: November 10, 2011Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: SANDEEP K. AGARWAL, DANIEL J. SCHNEIDER, MICHAEL B. BRENNER
-
Publication number: 20110245479Abstract: The present disclosure describes improved SELEX methods for producing aptamers that are capable of binding to target molecules and improved photoSELEX methods for producing photoreactive aptamers that are capable of both binding and covalently crosslinking to target molecules. Specifically, the present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. In addition, the disclosure describes aptamer constructs that include a variety of functionalities, including a cleavable element, a detection element, and a capture or immobilization element.Type: ApplicationFiled: May 23, 2011Publication date: October 6, 2011Applicant: SOMALOGIC, INC.Inventors: Dominic Zichi, Sheri K. Wilcox, Chris Bock, Daniel J. Schneider, Bruce Eaton, Larry Gold
-
Patent number: 7964356Abstract: The present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. This invention relates to the field of diagnostic histology, cytology, histopathology, and cytopathology methods and reagents for the detection of various disease states. More specifically, the invention relates to the use of aptamers in histologic, cytologic, histopathic, and/or cytopathic diagnostic methods. Aptamers may be provided that react with specific target molecules contained within a histological or cytological sample. Aptamers may be used to assess localization, relative density, and presence or absence of one or more target. Targets may be selected that are specific and diagnostic of a given disease state for which the sample was collected.Type: GrantFiled: July 9, 2009Date of Patent: June 21, 2011Assignee: SomaLogic, Inc.Inventors: Dominic Zichi, Sheri K. Wilcox, Chris Bock, Daniel J. Schneider, Bruce Eaton, Larry Gold
-
Publication number: 20110136099Abstract: The present disclosure describes methods, devices, reagents, and kits for the detection of one or more target molecules that may be present in a test sample. The described methods, devices, kits, and reagents facilitate the detection and quantification of a non-nucleic acid target (e.g., a protein target) in a test sample by detecting and quantifying a nucleic acid (i.e., an aptamer). The methods described create a nucleic acid surrogate for a non-nucleic acid target, thus allowing the wide variety of nucleic acid technologies, including amplification, to be applied to a broader range of desired targets, especially protein targets. The disclosure further describes aptamer constructs that facilitate the use of aptamers in a variety of analytical detection applications.Type: ApplicationFiled: December 2, 2010Publication date: June 9, 2011Applicant: SOMALOGIC, INC.Inventors: Daniel J. Schneider, Dan Nieuwlandt, Bruce Eaton, Marty Stanton, Shashi Gupta, Stephan Kraemer, Dominic Zichi, Larry Gold
-
Patent number: 7947447Abstract: The present disclosure describes improved SELEX methods for producing aptamers that are capable of binding to target molecules and improved photoSELEX methods for producing photoreactive aptamers that are capable of both binding and covalently crosslinking to target molecules. Specifically, the present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. In addition, the disclosure describes aptamer constructs that include a variety of functionalities, including a cleavable element, a detection element, and a capture or immobilization element.Type: GrantFiled: July 17, 2008Date of Patent: May 24, 2011Assignee: SomaLogic, Inc.Inventors: Dominic Zichi, Sheri K. Wilcox, Chris Bock, Daniel J. Schneider, Bruce Eaton, Larry Gold